M&AHealthcareCLOSED
Lanterne Dx Merges with Flagship Biosciences to Expand Capabilities
Acquirer
Lanterne Dx
Target
Flagship Biosciences
Lanterne Dx has completed a merger with Flagship Biosciences, enhancing its biomarker and digital pathology services. The combined entity will offer histopathology and biomarker validation to pharmaceutical and biotech clients.
✦ Meridian Analysis
This is an M&A transaction in the life sciences sector, specifically within contract research organizations (CROs). The merger aims to create a more comprehensive service offering for drug development and diagnostics.
The Meridian Weekly
The week's largest deals and the Iberian ones, every Monday. Free.